February 2026 Research Update

Two early treatment directions in Dravet models

This month, treatment-focused research was mostly early-stage and centered on Dravet mouse models, with one study also using human epilepsy brain tissue. Across these studies, the shared pattern was that targeting specific biological pathways reduced seizures or raised heat-seizure thresholds in mice, while also lowering signs of brain inflammation or increasing the SCN1A-related Nav1.1 protein. These results strengthen the idea that Dravet may have multiple treatable "pressure points," but they are not yet evidence of benefit in people. [1] [2]

One approach aimed at immune-like brain cells called microglia, focusing on an inflammatory pathway known as cGAS-STING-IFN-I. The study reported that this pathway was higher in microglia from drug-refractory epilepsy tissue and was also active in Dravet mice, and that reducing cGAS (genetically or with a brain-penetrant inhibitor) lowered seizure severity and reduced inflammatory gene signals in mice. The same work reported higher heat-triggered seizure thresholds and lower mortality in treated Dravet mice, linking inflammation-control to seizure-related outcomes in that model. [1]

A second approach tried to increase how much Nav1.1 protein is made from existing SCN1a messenger RNA, using a gene-therapy style tool (CIRTS-4GT3) delivered with AAV9 in Dravet mice. The study reported higher Nav1.1 protein in brain tissue without raising SCN1a mRNA, along with improved survival and a higher heat-triggered seizure threshold in treated mice. This supports the broader concept of "turning up" protein production for genes where one working copy is not enough, but it remains preclinical. [2]

Alongside these mouse studies, one laboratory chemistry project worked on new versions of soticlestat (a CYP46A1 inhibitor) to find compounds that inhibit the target enzyme more strongly in test-tube assays. Several compounds showed very strong CYP46A1 blocking, but some also strongly inhibited CYP3A4/5 in vitro, which raises early concerns about possible drug-drug interaction risk if such compounds were ever developed further. This was not a study in people or animals, so it mainly adds to early drug-development knowledge rather than near-term clinical change. [3]

What this means for patients and caregivers

These studies may matter later, because they point to new ways researchers are trying to reduce seizures in Dravet by either calming inflammatory signaling in the brain or boosting Nav1.1 protein levels. The evidence this month is still preclinical (mouse studies plus lab work), so it does not show that these strategies are safe or effective for people with Dravet syndrome yet. What became clearer is that both inflammation-related pathways and SCN1A protein production can be changed in models in ways that move seizure-related outcomes in a favorable direction. [1] [2] [3]

Important uncertainty remains about how well these mouse and lab results translate to day-to-day seizures, development, and safety in humans, and the studies did not provide human trial results. Still, they help explain why future treatments might not all look the same: some may aim to change immune-like signaling in brain support cells, while others may try to correct the downstream effects of SCN1A haploinsufficiency by increasing Nav1.1 protein. [1] [2]

Clearer picture of early behavior changes and family burden

This month added clearer human evidence about how Dravet affects early childhood behavior and how the condition affects families day-to-day. In young children with SCN1A-positive Dravet syndrome, behavior and social-emotional difficulties were reported to start early and become more pronounced with age through preschool years. Separately, a large caregiver survey highlighted that the financial burden can remain heavy even after reimbursement, showing that non-medical impacts are a major part of living with Dravet. [4] [5]

In a group of 58 children followed up to age 4, parent-report questionnaires showed that problem behaviors often began before age 3 and tended to worsen over time, including attention and hyperactivity-type concerns. Communication difficulties tracked with more severe behavior problems, suggesting these challenges often travel together rather than appearing in isolation. This helps place early behavior and communication supports into the larger story of Dravet as a condition that affects development as well as seizures, although the study did not test any intervention. [4]

In China, 161 caregivers reported that treatment costs frequently approached or exceeded what their household could afford, and many still paid a large share out-of-pocket after reimbursement. At the same time, most respondents expressed general satisfaction with existing medical security models, while also pointing to gaps in funding and coverage depth. Taken together, the survey adds concrete, patient-reported detail showing that insurance structure and access can shape the lived experience of Dravet, beyond medical symptoms alone. [5]

What this means for patients and caregivers

This theme matters now because it describes patterns families may recognize: behavioral and communication difficulties can appear early and may become more challenging during the toddler and preschool years, and financial strain can remain substantial even with reimbursement. The evidence here comes from human observational research, so it is useful for understanding what many families experience, but it cannot explain exactly why these changes happen for any one child. What became clearer this month is the timing (often before age 3) and direction (worsening with age) of reported behavior difficulties in early childhood, alongside the real-world costs families report. [4] [5]

Uncertainty remains about how much these patterns differ by treatment approach, seizure control, or other health factors, because the studies summarized experience rather than testing changes that might improve outcomes. Even so, they help set expectations for the kinds of challenges that may need attention alongside seizure management, including communication, behavior, and practical access to care. [4] [5]

Multiple brain systems show lasting changes in Dravet models

This month, several studies in Dravet mouse models converged on a similar message: SCN1A disruption can affect more than one brain network, and some changes persist across development. The studies pointed to altered inhibitory cell function, sensory thalamus wiring, and sleep-temperature control, which together can help explain why symptoms in Dravet can go beyond seizures alone. These are not clinical outcome studies, but they make the biology picture more connected by linking SCN1A-related changes to specific circuits. [6] [7] [8] [9]

In one cortical inhibitory neuron subtype called chandelier cells, electrical recordings in brain slices found reduced excitability in Dravet mice from juvenile stages into young adulthood, with little evidence of major shape changes. The authors noted this persistence as a contrast to other inhibitory cells (like basket cells) that may show more normalization with age in some models. This supports the idea that specific inhibitory circuits may remain vulnerable over time in Dravet. [6]

In the thalamus, the study found input-specific synaptic changes that were more persistent in one sensory-related region (VPL) than another (VPM). After seizure onset in Dravet mice, both excitatory and inhibitory input measures were reduced in VPL and stayed reduced into adulthood, while VPM showed mostly preserved excitatory input with more transient inhibitory changes. This pattern suggests that seizure onset may coincide with longer-lasting reorganization of certain sensory relay pathways in the Dravet model. [7]

Two studies focused on sleep and body temperature regulation, both highlighting that seizures and SCN1A changes can disrupt sleep-related brain control systems. One study reported that Dravet mice had lower core body temperature and did not show the usual temperature drop at sleep onset, and that warmth did not promote sleep unless SCN1A expression was restored or a hypothalamus region was stimulated. Another study reported that heat-triggered seizures reduced REM sleep shortly afterward and were linked to changes over time in a brainstem region involved in sleep (including fewer cholinergic neurons after repeated seizures). [8] [9]

A separate functional study of SCN1A variants at a single codon (I1347) showed that different changes at the same position can have very different effects on the NaV1.1 channel, ranging from complete loss-of-function to mixed functional patterns. This helps explain why SCN1A-related epilepsies can vary and why genetic results sometimes need careful interpretation beyond just the gene name. The study's own patient had a different SCN1A condition, an early-onset epilepsy that the authors describe as distinct from Dravet syndrome and needing different treatment considerations, and the channel tests were done in lab-grown cells, so what this means for people with Dravet remains uncertain. [10]

What this means for patients and caregivers

This theme mainly adds understanding for the future rather than changing care right now, because it is based on animal and laboratory studies. It helps clarify why Dravet syndrome can involve sleep problems, sensitivity to temperature, and developmental challenges alongside seizures, by identifying specific brain networks that may be affected by SCN1A changes and by seizures themselves. It also reinforces that "SCN1A-related" does not automatically mean the same channel behavior for every variant, which may be relevant when families read genetic reports. [6] [7] [8] [9] [10]

What remains uncertain is which of these circuit findings are most important for symptoms in people, and whether changing these circuits would improve daily functioning or seizure control. Even with that uncertainty, this month made the biology story more concrete by pointing to repeatable, circuit-level differences in inhibitory signaling, sensory relay pathways, and sleep-temperature regulation in Dravet models. [6] [7] [8] [9]

Signals from related populations and real-world triggers

A smaller set of studies this month looked at populations or questions adjacent to classic Dravet syndrome, offering context rather than direct answers about Dravet treatment outcomes. Fenfluramine was reported to reduce seizures in a small group with SCN1A-related GEFS+ (a related epilepsy syndrome), suggesting some SCN1A-associated epilepsies may respond well, though this was not studied in Dravet here. Another study captured parent reports that high ambient temperatures can worsen seizures in Dravet, which fits with long-standing concerns about heat sensitivity while documenting what families notice during heatwaves. [11] [12]

In 11 people with SCN1A-related GEFS+, adjunctive fenfluramine was reported to substantially reduce seizures, and EEG abnormalities improved in some participants, with only mild and transient side effects noted. Because there was no comparator group and the condition studied was GEFS+ rather than Dravet, the findings are best viewed as an early real-world signal about fenfluramine in a related SCN1A subgroup. Still, it adds to the broader picture that seizure response can vary across SCN1A-related epilepsies. [11]

In interviews with 19 parents of children and adolescents with Dravet syndrome, parents commonly described seizure worsening during heatwaves and high temperatures, and they also mentioned abrupt temperature changes and water exposure as triggers. Families reported using practical cooling and temperature-management strategies, and some described using fever-reducing medicines based on experience. Because this was qualitative research, it does not measure how often triggers cause seizures, but it documents shared lived experiences that may guide future studies of heat and seizure risk. [12]

What this means for patients and caregivers

This theme may matter now mainly as context: it adds patient-reported detail about heat as a trigger in Dravet and provides an early observational signal about a Dravet-approved medicine (fenfluramine) in a related SCN1A condition (GEFS+). The evidence is limited because one study was small and observational, and the other was qualitative interviews rather than measurements. Even so, the studies help clarify two practical points families often ask about: whether heat is commonly noticed as a trigger, and whether SCN1A-related epilepsies outside Dravet may also show strong seizure reduction with some established treatments. [11] [12]

What remains uncertain is how these GEFS+ results compare with Dravet outcomes in similar settings, and how much of the heat-trigger story varies by age, seizure type, or environment. This month did not test a standardized plan for managing heat exposure or measure heat-trigger frequency, but it did capture consistent caregiver descriptions that can inform future research questions. [12]

Broad genetic causes, with SCN1A prominent

One study this month reinforced how genetically diverse childhood epilepsies are, while also showing that SCN1A remains a common finding in genetic testing cohorts. In 87 children with unexplained epilepsy who were found to carry pathogenic or likely pathogenic variants, variants were spread across 48 different genes, with SCN1A among the most frequent. This does not focus only on Dravet syndrome, but it helps explain why genetic testing can clarify the underlying cause in some children with severe epilepsy presentations. [13]

The study also reported that many variants were de novo (new in the child), and that a large portion of cases could not be checked with family testing in the dataset. The authors emphasized the range of biological categories involved, from ion channels to structural and developmental genes, showing why epilepsy genetics often requires broad panels or exome testing rather than single-gene testing. For Dravet families, this mainly provides context about how often SCN1A appears in pediatric epilepsy genetics and how varied genetic causes can be across similar-looking syndromes. [13]

What this means for patients and caregivers

This theme is mostly background information rather than a change in Dravet research, because it studied a mixed pediatric epilepsy group rather than Dravet specifically. It may matter now for understanding why genetic answers can differ even among children with early-onset, hard-to-control seizures, and why SCN1A is a frequent gene in severe epilepsy cohorts. What remains uncertain from this report is how often testing finds an answer in all tested patients, because the study included only people already identified with pathogenic or likely pathogenic variants. [13]